Bioconnect Ireland event ‘Building clinician-enterprise teams to trial new products’

A challenge for many healthcare companies is to get their new products into use in clinical settings. Companies struggle to contact clinicians to make them aware of what they are developing and how their product can be used in daily clinical practice. Another important hurdle is how the healthcare company can become aware of products that are needed in clinicians practices: where there is s

CRA and clinician discuss a trial

The maxim “be not the first by whom the new are tried” is prevalent in many hospitals and general practice (for understandable reasons), but this state of mind drives Irish companies to different countries in order to sell their products where it can be challenging to market products not in use in their own country.pace for developing new products because of the absence of one or because of the inefficiency of an existing one.

The meeting explored the issues arising for the health service and clinicians in trialling new product as well as providing a showcase for companies and programmes which have overcome these barriers.

Among the key speakers Dr. Keith O’Neill (Director of Life Science and Food Commercialisation at Enterprise Ireland) underlined the importance of research and innovation, Fully one quarter of the entire EI budget is devoted to this area because in their experience companies that innovate grows. Dr Paul Anglim (Programme manager at BioInnovate Ireland), illustrated the Innovation Fellowship Programmes that focus on the development of solutions to address unmet clinical needs. All of BioInnovate programmes access and harness national and international leaders in academic, clinical and industry expertise within the medical device technology sector to deliver high quality unique training programmes. Dr. Colman Casey (CEO of Health Innovation Hub) illustrated how the Hub can create jobs allowing healthcare companies to quickly and successfully deliver commercial products and services testing products in a real life environment and refining the products to match the healthcare need. Dr. Fionnula Gibbons (Molecular Medicine Ireland) explained the role of MMI in supporting innovation and enhancing network creation.

The meeting was of particular relevance to the team here at Java Clinical Research. As a CRO operating in Ireland for the last 15 years, we recognise the clinical trial support needs of both established and emerging indigenous companies within the life science sector. We provide expert advice both in the development, planning and monitoring stages of clinical investigational programmes. Working with established networks of physicians, scientists, engineers and the biosciences industry, we can identify sites open to trials of innovative products, and ensure that clients benefit from rapid response enrolment coupled with local service and expertise. Java’s excellent in-house and contract laboratory services and unique technology platforms add value to studies of innovative products by providing more information from early stage clinical trials.

See more at: http://www.javacr.com